30 results about "Uvea" patented technology

A surgical technique wherein an indwelling shunt is placed in the eye of a patient having glaucoma. The shunt diverts aqueous humor from a deep scleral lake or directly from the anterior chamber to the suprachoroidal space from which it is removed by blood flowing in the choroidal and uveal tissues. This decreases the intra-ocular pressure. The indwelling shunt maintains the area of exposure of aqueous humor with the uvea by physically preventing scarring of the surrounding tissues. The method utilizes the 25 mm Hg driving force of the protein colloidal osmotic pressure of the blood to maximize the flow.

Delivery devices, systems and methods are provided for inserting an implant into an eye. The delivery or inserter devices or systems can be used to dispose or implant an ocular stent or implant, such as a shunt, in communication with the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space of the eye. The implant can drain fluid from an anterior chamber of the eye to a physiologic outflow path of the eye, such as, the suprachoroidal space, uveal scleral outflow pathway, uveoscleral outflow path or supraciliary space. Alternatively, or in addition, the implant can elute a drug or therapeutic agent. The delivery or inserter devices or systems can be used in conjunction with other ocular surgery, for example, but not limited to, cataract surgery through a preformed corneal incision, or independently with the inserter configured to make a corneal incision. The implant can be preloaded with or within the inserter to advantageously provide a sterile package for use by the surgeon, doctor or operator.

The methods and apparatus disclosed herein can be used to treat glaucoma of the eye. The methods and apparatus can be configured to apply energy to the sclera, cornea, and/or other regions of the eye in order to shrink collagenous tissue near Schlemm's canal. Juxtacanalicular treatment of the sclera and/or cornea adjacent Schlemm's canal can be used to dilate Schlemm's canal, collector channels, and/or the Trabecular Meshwork. The methods and apparatus can be configured to apply energy to the sclera to generate scleral vacuoles in the sclera to improve uveoscleral outflow.

The invention relates to a traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation. The traditional Chinese medicine monomer combination comprises the following components in parts by weight: 1.5 to 6.0 parts of ligustrazine, 0.5 to 1.5 parts of catalpol, 1.5 to 6.0 parts of ferulic acid, and 3.0 to 15 parts of paeoniflorin. According to the traditional Chinese medicine monomer combination, the conventional processing method is adopted and used for preparing injection, oral liquid, capsules, troches and preparations of other forms based on the traditional Chinese medicine monomer. The traditional Chinese medicine monomer combination is mainly used for resisting oxidization and protecting free radicals, can prevent and delay the deformation and development of cataract and improve the eyeground blood circulation, also can treat uvea and retina vascular diseases and eye malnutritional lesion, nourish optic nerve and recover visual functions from glaucoma, traumatic optic nerve diseases and visual pathway diseases.

The invention provides application of a small molecule in preparation of a mutant type uveal melanoma drug. The small molecule is elesclomol, and the mutant type uveal melanoma comprises GNAQ or GNA11 mutant type uveal melanoma. The small molecule elesclomol aims at the GNAQ/GNA11 mutant type uveal melanoma, can effectively kill mutant type UM cells, effectively inhibit proliferation of the mutant type UM cells, block the cell cycle to the G1 stage, can well inhibit proliferation and transfer of the GNAQ/GNA11 mutant type UM cells in vivo, and has a poor killing effect on wild type UM cells, thereby showing a specific killing effect on the GNAQ/GNA11 mutant type UM cells. The drug effect of the elesclomol is increased with the increase of the concentration, and the molecular structural formula of the elesclomol is shown as the formula (I) seeing the description.

Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind SLC45A2. The TCR may be utilized in various therapies, such as autologous cell transplantation, to treat a cancer, such as a cutaneous melanoma, uveal melanoma, a mucosal melanoma, or a metastatic melanoma. Methods for expanding a population of T cells that target SLC45A2 are also provided.

The invention provides a novel uveal melanoma metastasis risk prediction kit, and belongs to the field of disease molecular diagnosis kits. According to the kit, a relationship between a p.E725K mutation site of an EZH2 gene and uveal melanoma metastasis is elaborated; and the novel kit is provided, wherein the kit realizes effective prediction of the uveal melanoma metastasis risk by virtue of detection of the p.E725K mutation site of the EZH2 gene, and the kit has a good application prospect.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

Provided is a composition comprising a mutant Q209L-GNAQ DNA vaccine encoding, in a N-terminal to C-terminal direction, a fusion protein comprising VP22 or an HLA-binding sequence thereof, a mutant GNAQ sequence comprising a Q209L mutation, and a PADRE epitope. Also provided are methods of treatment and methods of vaccination comprising administering to a patient the composition. Also provided is a method of generating mutant GNAQ-specific T cells comprising priming T cells with ex vivo cultured dendritic cells transduced or electroplated with the composition.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.